Nishimura Koichi, Hirotani Shinichi, Okuhara Yoshitaka, Ando Tomotaka, Morisawa Daisuke, Oboshi Makiko, Sawada Hisashi, Eguchi Akiyo, Iwasaku Toshihiro, Naito Yoshiro, Masuyama Tohru
Cardiovascular Division, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan.
J Cardiol Cases. 2015 Aug 28;12(6):188-191. doi: 10.1016/j.jccase.2015.08.003. eCollection 2015 Dec.
A combination of hypertonic saline and furosemide has been proposed as a new therapeutic approach for treating acute decompensated heart failure (ADHF). The advantages of this combination have not only been demonstrated in ADHF but also in refractory ascites due to liver cirrhosis. However, the therapeutic effects of this regimen have never been evaluated in ADHF with overt diabetic nephropathy (ODN). Here, we present an interesting case of a 35-year-old patient admitted to our hospital for ADHF with shortness of breath and systemic edema, complicated with hypertension, type 2 diabetes, and ODN. Echocardiography showed left ventricular enlargement and diffuse hypokinesis, with ejection fraction of 33%. Urinary findings showed total proteinuria of 3597 mg/day during the first day of hospitalization. We initiated decongestion therapy with continuous infusion of hypertonic saline and furosemide. In spite of increased diuresis, edema remained the same and serum albumin decreased from 2.7 g/dl to 2.0 g/dl, and proteinuria increased up to 7344 mg/day. The amount of proteinuria and serum albumin level gradually recovered over time after cessation of the therapy. These data suggest that the combination therapy worsens glomerular hypertension and ODN. Therefore, hypertonic saline and furosemide combination therapy should not be recommended for patients with ODN. < Hypertonic saline and low-dose furosemide combination therapy has been proposed as a treatment option for ADHF, especially in refractory congestive heart failure cases. Nevertheless, the efficacy of this treatment in ADHF cases complicated with overt proteinuria is not fully elucidated. This therapy may induce increment of proteinuria in these patients due to aggravation of glomerular hypertension, and may be ineffective for decongestion or to treat edema.>.
高渗盐水和呋塞米联合使用已被提议作为治疗急性失代偿性心力衰竭(ADHF)的一种新的治疗方法。这种联合用药的优势不仅在ADHF中得到了证实,在肝硬化所致的顽固性腹水中也得到了证实。然而,这种治疗方案对伴有显性糖尿病肾病(ODN)的ADHF患者的治疗效果从未得到评估。在此,我们报告一例有趣的病例,一名35岁患者因ADHF伴呼吸急促和全身性水肿入住我院,并发高血压、2型糖尿病和ODN。超声心动图显示左心室扩大和弥漫性运动减弱,射血分数为33%。尿液检查结果显示,住院第一天的总蛋白尿为3597毫克/天。我们开始采用持续输注高渗盐水和呋塞米进行去充血治疗。尽管利尿增加,但水肿仍未减轻,血清白蛋白从2.7克/分升降至2.0克/分升,蛋白尿增加至7344毫克/天。停止治疗后,蛋白尿水平和血清白蛋白水平随时间逐渐恢复。这些数据表明,联合治疗会加重肾小球高血压和ODN。因此,不建议ODN患者使用高渗盐水和呋塞米联合治疗。<高渗盐水和低剂量呋塞米联合治疗已被提议作为ADHF的一种治疗选择,特别是在难治性充血性心力衰竭病例中。然而,这种治疗对并发显性蛋白尿的ADHF病例的疗效尚未完全阐明。这种治疗可能会因肾小球高血压加重而导致这些患者蛋白尿增加,并且可能对去充血或治疗水肿无效。>